<DOC>
	<DOCNO>NCT03035864</DOCNO>
	<brief_summary>The propose phase II study single-centre , randomize , double mask , parallel arm , vehicle-controlled trial , design evaluate preliminary efficacy safety rhNGF eye drop 20 µg/ml concentration administer six time daily 8 week patient underwent cataract corneal refractive surgery , know damage corneal sensory nerve plexus . After confirmation inclusion exclusion criterion eligible patient randomize 2:1 ratio rhNGF vehicle control treatment 8 week study treatment administration 4 week Follow-up .</brief_summary>
	<brief_title>A 8 Weeks Study With 4 Weeks Follow-up Evaluate Preliminary Efficacy Safety Recombinant Human Nerve Growth Factor Eye Drops Solution Versus Vehicle Patients After Cataract Refractive Surgery</brief_title>
	<detailed_description />
	<mesh_term>Cataract</mesh_term>
	<mesh_term>Capsule Opacification</mesh_term>
	<mesh_term>Mitogens</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<mesh_term>Tetrahydrozoline</mesh_term>
	<criteria>1 . Male female ≥18 year old 2 . Patients characterize follow clinical feature : 1 . History cataract refractive corneal surgery study eye ( ) previous 6 month ; 2 . Mean Symptom Assessment Dry Eye ( SANDE ) score severity frequency least 30 baseline 3 . The eye ( study eye ) must fulfill criterion 4 . Best correct distance visual acuity ( BCDVA ) score ≥ 0.1 decimal unit eye time study enrolment 5 . Female patient must negative pregnancy urine test childbirth potential . 6 . Only patient satisfy requirement inform consent may include study . Written Informed Consent must obtain initiation studyspecific procedure . 7 . Patients must ability willingness comply study procedures 1 . Any ocular disease Dry Eye require treatment topical medication either eye time study enrolment . 2 . Any active ocular infection active inflammation either eye unrelated Dry Eye . 3 . Presence history systemic ocular disorder , condition disease ( particular attention malignancy neurooncological disease ) could possibly interfere conduct require study procedure interpretation study result . 4 . Use therapeutic Refractive Contact lenses either eye time study enrolment ; 5 . History ocular surgery study eye ( ) , exclude corneal refractive cataract procedure , within 90 day study enrolment . 6 . Females childbearing potential ( surgically sterilize postmenopausal least 1 year ) exclude participation study meet one follow condition : 1. currently pregnant , 2. positive result urine pregnancy test ( Baseline/Day 0 ) , 3. intend become pregnant study treatment period , 4. breastfeeding , 5. willing use highly effective birth control measure , : hormonal contraceptive oral , implanted , transdermal , injected and/or mechanical barrier method spermicide conjunction barrier condom diaphragm IUD ( Intrauterine device ) entire course 30 day study treatment period . 7 . Participation another clinical study time present within 30 day study enrolment ; 8 . History drug , medication alcohol abuse addiction .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Ocular discomfort cataract refractive surgery</keyword>
	<keyword>cataract surgery</keyword>
	<keyword>refractive surgery</keyword>
</DOC>